Gapping up
In reaction to earnings/guidance:
- RLGT +16.5%, CWH +8.1%, EXLS +6.9%, SMG +6%, NEE +5.9% (also announces 4-for-1 stock split), COOP +4.8%, DAVA +3.3%, MMM +1.5% (August sales), KHC +1.4% (updated outlook)
Other news:
- MRNS +54% (announces "positive" top-line results from Phase 3 Marigold Study)
- ABUS +15.6% (announces AB-729 90 mg single-dose week 12 data in chronic Hepatitis b subjects demonstrating significant and continuous reductions in HBsAg)
- FCAU +11.4% (FCAU and Peugeot amend combination agreement)
- MDC +10.9% (says sharp increase in demand for new homes has extended into Q3)
- NVAX +7.2% (announces COVID-19 vaccine manufacturing agreement with Serum Institute of India, increasing novavax' global production capacity to over 2 billion doses annually)
- AERI +4.8% (announces FDA approval of its Athlone, ireland facility for production of Rhopressa 0.02%)
- BNTX +4.4% (to receive up to €375 mln in funding from German Federal Ministry of Education and Research to support COVID-19 vaccine program BNT162)
- GRAF +4% (scheduled the special meeting of its stockholders to approve its proposed business combination with Velodyne Lidar for September 29)
- NYMT +3.5% (raises dividend)
- PBR +2.7% (reports on the revision of the Exploration & Production (E&P) segment portfolio in face of the crisis caused by COVID-19)
- IAC +2.6% (provides August performance metrics for ANGI)
- SKT +2.5% (provides operational update)
- CTRN +2.2% (reaffirms Q3 comp guidance; reinstates share repurchase program)
- SCM +2.1% (declares special quarterly dividend for Q4 of $0.06 per share)
- LPTX +1.5% (mixed shelf offering)
- MYL +1.4% (Mylan N.V. and Pfizer (PFE) receive final approval from the European Commission (EC) for the proposed combination of Mylan and Pfizer Inc.'s Upjohn business)
Analyst comments:
- PLT +4.9% (upgraded to Neutral from Underweight at JP Morgan)
- RIO +3.7% (upgraded to Overweight from Neutral at JP Morgan; upgraded to Equal Weight from Underweight at Barclays)
- TTD +3.4% (initiated with an Overweight at KeyBanc Capital Markets)
- WU +3.3% (upgraded to Buy from Neutral at BofA Securities)
- ROKU +3.1% (initiated with an Overweight at KeyBanc Capital Markets)
- CYBR +3% (upgraded to Overweight from Equal Weight at Barclays)
- NEP +2.9% (upgraded to Overweight from Equal Weight at Wells Fargo)
- CX +2.8% (upgraded to Buy from Neutral at Goldman)
- BHP +1.9% (upgraded to Buy from Neutral at Goldman)
- NFLX +1.8% (initiated with an Overweight at KeyBanc Capital Markets)
- FB +1.2% ( initiated with an Overweight at KeyBanc Capital Markets)
- VFC +1.1% (upgraded to Buy from Neutral at BTIG Research)
- GOOG +0.9% (initiated with an Overweight at KeyBanc Capital Markets)